Warburg-Backed Hong Kong Firm That Uses AI for Drug Discovery Files for U.S. IPO
- Insilico Medicine filed application confidentially last week
- Company could seek to raise about $300 million from listing
This article is for subscribers only.
Insilico Medicine, a Hong Kong-based company that uses artificial intelligence to drive drug discovery, filed confidentially for a U.S. initial public offering last week, according to people familiar with the matter.
The Warburg Pincus-backed firm is working with advisers on the first-time share sale and is looking to raise around $300 million, the people said, asking not to be identified because the matter is private.